Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression
The Oncologist · 06.02.2025 · 30 (2)
DOI: 10.1093/oncolo/oyae238 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 21.09.2024. Verfasst von Yoonjin Kwak und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Claudins, Biomarkers, Tumor, Adenocarcinoma. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Claudin 18.2 (CLDN18.2) is a promising target for targeted therapies in gastric cancer (GC). This study investigated the prevalence of CLDN18.2 expression in patients with stages II-IV GC or gastroesophageal junction (GEJ) adenocarcinoma and its correlation with clinicopathologic features and other crucial GC biomarkers.
Methods
We enrolled 1000 patients diagnosed with stages II-IV GC after surgical treatment. Immunohistochemistry for CLDN18 (43-14A clone), PD-L1 (22C3 pharmDx), HER2, and FGFR2 was performed. CLDN18.2 positivity was defined as moderate-to-strong (2+/3+) membranous staining in ≥75% of tumor cells. CLDN18.2 expression was compared with biomarker expression, Epstein-Barr virus (EBV) association and microsatellite instability status, and clinicopathologic features.
Result
CLDN18.2 was positive in 34.4% of the patients. CLDN18.2 positivity was significantly higher in the middle and upper thirds than in the lower third gastric location (P < .001), but there was no correlation with age, sex, or stage (P > .05). CLDN18.2 positivity was rare (2.8%) in mucinous adenocarcinoma but frequent (90.9%) in a majority of gastric carcinomas with lymphoid stroma. CLDN18.2 positivity was higher in EBV-associated (P < .001) and PD-L1-positive (PD-L1 CPS ≥ 5) GC (P = .014) but lower in HER2 positive GC (P = .005). CLDN18.2 positivity was not significantly associated with overall survival and disease-free survival.
Conclusion
This study provides a comprehensive evaluation of CLDN18.2 status and its correlation with the clinicopathologic characteristics of patients with stages II-IV GC in Korea and with crucial biomarkers. It may be valuable for guiding future drug development, expanding treatment options, and ultimately improving patient outcomes in GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Department of Interdisciplinary Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea.
- Medical Affairs, Astellas Pharma Korea Inc., Seoul, Korea.
- Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
- Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
ORCID-Profile: Hyuk-Joon Lee, Han-Kwang Yang, Hye Seung Lee
Zitieren
APA
Kwak, Y., Kim, T. Y., Nam, S. K., Hwang, H. J., Han, D., Oh, H. J., Kong, S. H., Park, D. J., Oh, D. Y., Lee, H. J., Im, S. A., Yang, H. K., & Lee, H. S. (2025). Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. The Oncologist, 30(2). https://doi.org/10.1093/oncolo/oyae238
Vancouver
Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ, et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. The Oncologist. 2025;30(2). doi:10.1093/oncolo/oyae238
BibTeX
@article{Kwak2025,
author = {Kwak, Yoonjin and Kim, Tae-Yong and Nam, Soo Kyung and Hwang, Hye Jung and Han, Daeyoung and Oh, Hyeon Jeong and Kong, Seong-Ho and Park, Do Joong and Oh, Do-Youn and Lee, Hyuk-Joon and Im, Seock-Ah and Yang, Han-Kwang and Lee, Hye Seung},
title = {Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {2},
doi = {10.1093/oncolo/oyae238}
}
EUVIMED